Objective  To establish the drug use evaluation (DUE) standard of fibrinogenase for injection and provide a  reference for the rational clinical application of fibrinogenase for injection.

Methods  Based on the specification of fibrinogenase for injection, the DUE standard was established from three aspects: drug indication, drug process and drug results, with reference to relevant guidelines and literature, and through discussion with clinical experts. A retrospective survey was conducted to evaluate the inpatients using fibrinogenase for injection from January 2021 to December 2021 in Ningde Hospital of Traditional Chinese Medicine, Fujian Province.

Results  A total of 256 patients were included, with a medication reasonable rate of 61.72%. The irrational use of drugs was mainly including the inappropriate usage and dosage (3.91%), off-label medication (1.95%), no skin test (8.98%), too long or inadequate course of medication (25.00%).

Conclusion  The DUE standard established of fibrinogenase for injection is scientific, practical and feasible. The use of fibrinogenase for injection in contraindications and high blood coagulation state, and off-label medication can be further optimized.

1.林小娟, 黄小红, 黄涓涓, 等. 利伐沙班药物利用评价标准的建立与应用[J]. 中国现代应用药学, 2020, 37(20): 2543-2548. [Lin XJ, Huang XH, Huang JJ, et al. Establishment and application of drug use evaluation standard of rivaroxaban[J]. Chinese Journal of Modern Applied Pharmacy, 2020, 37(20): 2543-2548.] DOI: 10.13748/j.cnki.issn1007-7693.2020.20.020.

2.王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. [Wang QY, Wu MF, Liu X, et al. Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021[J]. Chinese Journal of Clinical Pharmacology, 2021, 37(21): 2999-3016.] DOI: 10.13699/j.cnki.1001-6821.2021.21.032.

3.袁浩宇, 林勇, 胡明, 等. 药物利用评价标准建立的方法探讨及实践[J]. 中国药房, 2010, 21(22): 2101-2104. [Yuan HY, Lin Y, Hu M, et al. Exploration on the method for establishment of DUE standard and practical study[J]. China Pharmacy, 2010, 21(22): 2101-2104.] http://www.cnki.com.cn/Article/CJFDTOTAL-ZGYA201022036.htm.

4.邢蓉, 宋佳伟, 许健, 等. 头孢哌酮舒巴坦基于加权TOPSIS法的药物利用评价[J]. 中国医院药学杂志, 2014, 34(15): 1273-1278. [Xing R, Song JW, Xu J, et al. Evaluation on cefperazone-sulbactam drug administration based on weighted TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2014, 34(15): 1273-1278.] DOI: 10.13286/j,cnki,chinhosppharmacyj.2014.15.09.

5.李素琼, 班立丽. 国内外药物利用评价研究综述[J]. 中国医院用药评价与分析, 2021, 21(7): 893-896. [Li SQ, Ban LL. Review on drug use evaluation at home and abroad[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2021, 21(7): 893-896.] DOI: 10.14009/j.issn.1672-2124.2021.07.028.

6.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

7.王慧林. 他汀类药物联合注射用纤溶酶对短暂性脑缺血发作患者血液流变学及血脂水平的影响[J]. 现代诊断与治疗, 2020, 31(13): 2074-2076. [Wang HL. Effect of statins plus plasmin for injection on hemorheology and lipid levels in patients with transient ischemic attack[J]. Modern Diagnosis and Treatment, 2020, 31(13): 2074-2076.] http://www.cnki.com.cn/Article/CJFDTOTAL-XDZD202013028.htm.

8.Ma B, Zhang Y, Wu D, et al. Affinity-purification of fbrinogenase with high proteolytic activity from agkistrodon halys (Chinese) venom[J]. Arch Pharm Res, 2008, 31(9): 1129-1136. DOI: 10.1007/s12272-001-1279-1.

9.白丽淼, 顾平. 注射用纤溶酶合理应用点评标准的建立及应用[J]. 中国处方药, 2021, 19(9): 74-76. [Bai LM, Gu P. Establishment and application of evaluation standard for rational use of fibrinogenase injection[J]. Journal of China Prescription Drug, 2021, 19(9): 74-76.] http://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202109036.htm.

10.王霞, 陈彩梅. 耳后注射甲泼尼龙琥珀酸钠联合纤溶酶治疗重度及极重度突发性耳聋患者的疗效观察[J]. 血栓与止血学, 2022, 28(2): 225-227. [Wang X, Chen CM. Clinical observation of methylprednisolone sodium succinate combined with fibrinolytic enzyme in the treatment of severe and very severe sudden deafness[J]. Chinese Journal of Thrombosis and Hemostasis, 2022, 28(2): 225-227.] DOI: 10.3969/j.issn.1009-6213.2022.02.018.

11.张玉娟, 王秀兰. 6例纤溶酶致不良反应的观察及护理[J]. 中国现代药物应用, 2010, 4(15): 171-172. [Zhang YJ, Wang XL. Observation and nursing care of 6 cases of adverse reactions caused by plasmin[J]. Chinese Journal of Modern Drug Application, 2010, 4(15): 171-172.] DOI: 10.14164/j.cnki.cn11-5581/r.2010.15.101.

12.李倩. 纤溶酶注射液在脑梗死急性期治疗效果的评价[J]. 中外医学研究, 2017, 15(33): 66-67. [Li Q. Evaluation of the therapeutic effect of fibrinolytic enzyme injection in the acute phase of cerebral infarction[J]. Chinese and Foreign Medical Research, 2017, 15(33): 66-67.] DOI: 10.14033/j.cnki.cfmr.2017.33.031.

13.刘爱妮, 于向红, 刘泽涛. 血液高凝状态下应用纤溶酶预防血栓形成疗效观察与探究[J]. 医学理论与实践, 2012, 25(3): 295-296. [Liu AN, Yu XH, Liu ZT. Observation and exploration of the therapeutic effect of using plasmin to prevent thrombosis in hypercoagulable blood[J]. The Journal of Medical Theory and Practice, 2012, 25(3): 295-296.] DOI: 10.19381/j.issn.1001-7585.2012.03.025.

14.安乾, 王兵, 崔文军, 等. 贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症的临床观察[J]. 中国药房, 2017, 28(29): 4099-4102. [An Q, Wang B, Cui WJ, et al. Clinical observation of beraprost combined with fibrinogenase in the treatment of lower extremity atherosclerotic occlusive disease[J]. China Pharmacy, 2017, 28(29): 4099-4102.] DOI: 10.6039/j.issn.1001-0408.2017.29.18.

15.姜丽, 王利军, 赵岚, 等. 纤溶酶对急性脑梗死患者血浆血栓前体蛋白水平的影响及意义[J]. 临床神经病学杂志, 2015, 28(2): 140-142. [Jiang L, Wang LJ, Zhao L, et al. Effects and the significance of fibrinogenase on plasma thrombus precursor protein level in patients with acute cerebral infarction[J]. Journal of Clinical Neurology, 2015, 28(2): 140-142.] http://cdmd.cnki.com.cn/Article/CDMD-10062-1016703703.htm.

16.郑洋, 孙霈, 董青, 等. 恶性肿瘤高凝状态发病机制与诊断标准探讨[J]. 中国医刊, 2014, 49(5): 16-20. [Zheng Y, Sun P, Dong Q, et al. Discussion on the pathogenesis and diagnostic criteria of hypercoagulable state of malignant tumors[J]. Chinese Journal of Medicine, 2014, 49(5): 16-20.] DOI: 10.3969/j.issn.1008-1070.2014.05.006.

17.宋佳伟, 王媛媛, 陈慧娟, 等. 安罗替尼药物利用评价标准的建立及应用[J]. 中国新药与临床杂志, 2022, 41(4): 245-249. [Song JW, Wang YY, Chen HJ, et al. Establishment and application of drug use evaluation criteria for anlotinib[J]. Chinese Journal of New Drugs and Clinical Remedies, 2022, 41(4): 245-249.] DOI: 10.14109/j.cnki.xyylc.2022.04.11.

18.刘碧丽, 吴小枫, 杨嘉永, 等. 25例注射用纤溶酶不良反应报告分析[J]. 中国卫生标准管理, 2020, 11(7): 112-114. [Liu BL, Wu XF, Yang JY, et al. Adverse reactions analysis of fibrinogenase for injection from 25 cases[J]. China Health Standard Management, 2020, 11(7): 112-114.] DOI: 10.3969/j.issn.1674-9316.2020.07.043.